Here are the Endoscopic duodenal-jejunal bypass liner treatment of moderate obstructive sleep apnoea—A pilot study journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Laparoscopic duodenal perforation, cpt code for laparoscopic duodenal switch, endoscopic duodenal jejunal bypass liner treatment for covid, endoscopic duodenal jejunal bypass liner treatment for prostate, endoscopic duodenal jejunal bypass liner treatment for vertigo, laparoscopic duodenal switch surgery.
Endoscopic duodenal-jejunal bypass liner treatment of moderate obstructive sleep apnoea—A pilot study
We aimed to assess the extent to which people with type 2 diabetes or pre-diabetes, obesity (BMI 30–45 kg/m2) and moderate obstructive sleep apnoea (OSA) requiring continuous positive airway pressure ventilation (CPAP) were able to discontinue CPAP following EndoBarrier-related weight loss. We assessed sleep and metabolic parameters before, during and after EndoBarrier in 12 participants with moderate OSA requiring CPAP (75% female, 8/12 [66%] type 2 diabetes, 4/12 [34%] prediabetes, mean ± SD age 52.6 ± 9.7 years, BMI 37.4 ± 3.5 kg/m2, median duration of OSA while on CPAP 9.0 [7.0–15.0] months). With EndoBarrier in-situ, mean ± SD Apnoea Hypopnoea Index (AHI) fell by 9.1 ± 5.0 events/h from 18.9 ± 3.8 to 9.7 ± 3.0 events/h (p <.001) with an associated reduction in symptoms of daytime sleepiness (mean Epworth Sleepiness Score) such that all the 12 participants no longer required CPAP according to National Institute for Health and Care Excellence criteria. After End oBarrier removal, 10/12 (83%) patients attended follow-up and at 12 months after removal, AHI remained below 15 in 5/10 (50%) patients but in other five the AHI rose above 15 such that restarting CPAP was recommended as justified by their symptoms. Rather than restart CPAP, two patients lost the regained weight and their AHI dropped below 15 again. Thus, 7/10 (70%) of patients were able to remain off CPAP 12 or more months after EndoBarrier removal. These results demonstrate major benefit of EndoBarrier in moderate OSA, allowing all patients to discontinue CPAP during treatment, and with maintenance of improvement at follow-up in 70%. They confirm previously demonstrated metabolic improvements in diabetes and obesity. © 2024 The Author(s). Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Authors : Yadagiri M.; Kinney F.Y.; Ashman N.; Bleasdale J.P.; Fogden E.N.; Anderson M.R.; Walton C.; Greenstone M.A.; Ryder R.E.J.
Source : John Wiley and Sons Inc
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1111/cob.12694 |
| ISSN | 17588103 |
| Volume | 14 |
You can download the article here
If You have any problem, contact us here